MAP2K7 and plasma cell myeloma: Due to this cancer-selective mode of action, GADD45β/MKK7 inhibitors demonstrated no adverse effects, alongside a cancer-selective pharmacodynamic response, in their first-in-human study in refractory multiple myeloma patients.